Cailin Conner

Urban Health Today

Advancements in medical research led to the introduction of biologic therapies in 2015, revolutionizing the treatment of severe asthma. The Journal of Managed Care and Specialty Pharmacy published a cross-sectional study evaluating in-hospital asthma outcomes prior to (2012-2014) and following (2016-2018) the implementation of biologic therapies for asthma.
The study collected data from the Nationwide Readmissions Database, focusing on patients aged &gt;2 years hospitalized for asthma between 2012 and 2018. The researchers assessed various outcomes, including rates of asthma hospital admission, asthma-related 30-day readmission, hospital length of stay, hospital costs, and inpatient mortality. Generalized linear models were used to analyze the trends in these outcomes quarterly during the periods 2012-2014 and 2016-2018.
The results of the study revealed several positive trends in in-hospital outcomes following the introduction of biologic therapies for asthma, including:
<ol>
<li>Decreased asthma hospital admission rates: The study observed a significant decrease in quarterly asthma admission rates (-0.90%) during 2016-2018. This decline was primarily observed among adults and was not evident during 2012-2014.</li>
<li>Decreased asthma-related 30-day readmission rates: Both the periods 2012-2014 and 2016-2018 exhibited a decrease in quarterly readmission rates for asthma patients. During 2012-2014, the rates decreased by 2.40%. During 2016-2018, they decreased by 2.12%.</li>
<li>Decreased hospital length of stay: The mean length of stay for asthma admissions decreased quarterly by 0.44% during 2012-2014 and by 0.27% during 2016-2018.</li>
<li>Stable inpatient mortality rates: There were no significant trends in inpatient mortality rates during both periods, indicating that the introduction of biologic therapies did not adversely affect mortality outcomes.</li>
</ol>
While the study demonstrates positive outcomes, it is important to consider a few limitations. The analysis was based on data from the Nationwide Readmissions Database, which may not capture all relevant variables and factors influencing asthma outcomes. The study also focused on in-hospital outcomes and did not account for outpatient management or long-term follow-up data.
The researchers reported, “following the introduction of novel controller therapies such as biologics, there was a decreasing trend in asthma-related hospital admissions and readmissions although hospital costs increased.” However, further research is necessary to explore the impact of recently developed biologic therapies on health and economic outcomes associated with asthma.
Source: <a href="https://www.jmcp.org/doi/10.18553/jmcp.2023.29.7.721" target="_blank" rel="noopener">Journal of Managed Care and Specialty Pharmacy</a>

Lou Portero

Marketing and Safety Issues Surrounding Compounded GLP-1 Receptor Agonists

Diabetes

Rob Dillard

Cultural Competence in Alzheimer's Care

Video Insights

Measles Makes an Unwelcome Return

Infectious Diseases

Latest News

Biologic Therapies Show Positive Impact on In-Hospital Outcomes for Asthma Patients

Asthma

Introducing biologic therapies for severe asthma led to significant reductions in asthma-related hospital admissions and readmissions, while inpatient mortality rates remained stab

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe